Table 2. Completed phase III randomized trials of targeted therapies in SCLC.

Author (ref.)	Study population	Treatment	NO. patients	OS (months)	Comments
Rigas JR et al. (14)	Patients in CR and PR	BAY 12-9566 vs. control	327	3.2 vs. 5.3 P=0.05	Negative
Shepherd FA et al. (15)	Response to first-line chemotherapy in SCLC patients	Marimastat vs. control	266 vs. 266	9.3 vs. 9.7 P=0.90	Negative
Pujol JL et al. (16)	ED SCLC after response to chemotherapy	Thalidomide vs. control	49 vs. 42	11.7 vs. 8.7 P=0.16	Negative, but thalidomide had a significantly longer survival in patients with a PS of 1 or 2 (P=0.02)
Lee SM et al. (17)	LD and ED SCLC	Thalidomid ± chemotherapy	724	10.1 vs. 10.5 P=0.28	Negative
Giaccone G et al. (66)	LD SCLC after response to chemotherapy	BEC-2 vs. control	515	14.3 vs. 16.4 P=0.28	Negative

ED, extensive-stage disease; SCLC, small cell lung cancer; CR, complete response; PR, partial response; LD, limited-stage disease; PS, performance status; OS, overall survival.